BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsEarnings

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni,

Related news

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

SRPTSarepta Therapeutics2026-07-22 12:30 EST

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SGMOSangamo Therapeutics, Inc.2026-05-14 20:01 EST

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

SGMOSangamo Therapeutics, Inc.2026-03-30 20:01 EST

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
51.64 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States